RECRUITINGINTERVENTIONAL

IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)

Evaluation of a Proactive Identification and Digital Mental Health Intervention Approach to Address Unmet Psychosocial Needs of Individuals Living With Likely Incurable Cancer

About This Trial

The purpose of this research study is to evaluate a mobile application (app) for depression treatment called "Moodivate" among cancer survivors. Moodivate was developed by our research team to assist with the treatment of depressed mood. Participants will be randomly assigned to either download the mobile app, "Moodivate", or not. Approximately 2/3 of participants enrolled will receive the mobile app and the remaining 1/3 will not. All participants will complete electronic questionnaire measures throughout the study period. Questionnaires will assess symptoms of depression, as well as your experiences using Moodivate and participating in this trial. Participation in this study will take about 12 weeks, beginning today. Participation in this study may help in the treatment of future cancer survivors. The greatest risks of this study include frustration, worsening of emotional distress, data breach, and/or loss of confidentiality. Alternative treatments include contacting your primary care provider or your oncology care team to discuss other available treatments for depressed mood.

Who May Be Eligible (Plain English)

Who May Qualify: - Age \> 18 years - ILLIC (as determined during manual chart review) - Elevated depressive symptoms, defined as a score of ≥ 8 on the PHQ-9 - Current owner of an iOS- or Android-compatible smartphone - Willingness to utilize a mobile app for the treatment of depressed mood (response of "yes" on yes/no item) - Have a valid e-mail address that is checked regularly or have regular access to text messages (to access follow-up assessments) - English language fluency Who Should NOT Join This Trial: - Current suicidal ideation at study screening, defined as a response greater than or equal to 1 on item nine of the PHQ-9 - Severe cognitive impairment that precludes completion of willing to sign a consent form. For the purposes of assessing eligibility, this criterion is operationalized as: - Prior diagnosis of dementia, or Major Neurocognitive Disorder indicated either via self-report or in the EHR; or - Self-report of cognitive difficulties that impair functional independence Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * Age \> 18 years * ILLIC (as determined during manual chart review) * Elevated depressive symptoms, defined as a score of ≥ 8 on the PHQ-9 * Current owner of an iOS- or Android-compatible smartphone * Willingness to utilize a mobile app for the treatment of depressed mood (response of "yes" on yes/no item) * Have a valid e-mail address that is checked regularly or have regular access to text messages (to access follow-up assessments) * English language fluency Exclusion Criteria: * Current suicidal ideation at study screening, defined as a response greater than or equal to 1 on item nine of the PHQ-9 * Severe cognitive impairment that precludes completion of informed consent. For the purposes of assessing eligibility, this criterion is operationalized as: * Prior diagnosis of dementia, or Major Neurocognitive Disorder indicated either via self-report or in the EHR; or * Self-report of cognitive difficulties that impair functional independence

Treatments Being Tested

BEHAVIORAL

Behavioral Activation Therapy App

Moodivate focuses on tracking daily activities, recording daily mood, and identifying new activities to complete that may help improve mood. Participants will be asked to complete questionnaire measures weekly for 8 weeks, with a final follow-up questionnaire at 12 weeks following study enrollment.

BEHAVIORAL

Treatment as Usual

Participants will be provided educational material about mood management available via the EHR with the suggestion to discuss questions with their oncology provider. Participants will be asked to complete questionnaire measures weekly for 8 weeks with a final follow up at week 12.

Locations (1)

Medical University of South Carolina

Charleston, South Carolina, United States